The histone deacetylase (HDAC) enzymes, a class of epigenetic regulators, are historically
well established as attractive therapeutic targets. During investigation of trends within …

Angioimmunoblastic T-cell lymphoma (AITL) is an uncommon subtype of mature peripheral
T-cell lymphoma (PTCL). The history of AITL is much longer and deeper than the literature …

PURPOSE Romidepsin, a histone deacetylase inhibitor, has demonstrated activity in
relapsed or refractory peripheral T-cell lymphoma (PTCL) as a single agent …

Background Based on the encouraging activity and manageable safety profile observed in a
phase 1 study, the ECHELON-2 trial was initiated to compare the efficacy and safety of …

Angioimmunoblastic T-cell lymphoma (AITL) is a unique subtype of peripheral T-cell
lymphoma (PTCL) with distinct clinicopathologic features and poor prognosis. We performed …

The incidence of lymphoma has gradually increased over previous decades, and it ranks
among the ten most prevalent cancers worldwide. With the development of targeted …

Modulating epigenetic modification has been recognized for over a decade as an effective
therapeutic approach to cancer and many studies of histone deacetylase (HDAC), one of the …

Peripheral T-cell lymphomas (PTCL) are a group of rare malignancies characterized by
chemotherapy resistance and poor prognosis. Romidepsin and pralatrexate were approved …

Peripheral T-cell lymphoma (PTCL) is a rare and heterogeneous group of clinically
aggressive diseases associated with poor prognosis. Except for ALK+ anaplastic large-cell …

Despite considerable advances in the treatment of lymphoma, the prognosis of patients with
relapsed and/or refractory disease continues to be poor; thus, a continued need exists for …